Cargando…
Emerging RAS-directed therapies for cancer
RAS oncogenes are the most commonly mutated oncogenes in human cancer, and RAS-mutant cancers represent a major burden of human disease. Though these oncogenes were discovered decades ago, recent years have seen major advances in understanding of their structure and function, including the therapeut...
Autores principales: | Conroy, Michael, Cowzer, Darren, Kolch, Walter, Duffy, Austin G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OAE Publishing Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094076/ https://www.ncbi.nlm.nih.gov/pubmed/35582302 http://dx.doi.org/10.20517/cdr.2021.07 |
Ejemplares similares
-
Targeting KRAS in Pancreatic Cancer
por: Cowzer, Darren, et al.
Publicado: (2022) -
Dynamic regulation of RAS and RAS signaling
por: Kolch, Walter, et al.
Publicado: (2023) -
The Ins and Outs of RAS Effector Complexes
por: Kiel, Christina, et al.
Publicado: (2021) -
Advanced Bile Duct Cancers: A Focused Review on Current and Emerging Systemic Treatments
por: Cowzer, Darren, et al.
Publicado: (2022) -
Hidden Targets in RAF Signalling Pathways to Block Oncogenic RAS Signalling
por: Nolan, Aoife A., et al.
Publicado: (2021)